ArticleMolecular medicine (Cambridge, Mass.)1998
Curcumin is an in vivo inhibitor of angiogenesis.
Article in Molecular medicine (Cambridge, Mass.), 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03845322 (Clinical Action of Curcumin/Turmeric in Chronic Subdural Hematoma Recurrence), which is not on this map. Cited by 122 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Action of Curcumin/Turmeric in Chronic Subdural Hematoma Recurrence
Who cites it
122 citing papers in PubMed, 1 synthesis or guideline pooled it, 402 citations in OpenAlex.
- Curcumin for maintenance of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2012Pooled it
- Curcuma longa as additive in the diet for Astyanax aff. bimaculatus.Fish physiology and biochemistry · 2017Trial
- Genistein and Curcumin Inhibit Proliferation and Invasiveness in BRAFV600E Mutant and Wild-Type Melanoma Cells: Insights into Their Anticancer Effects.Biomedicines · 2025Article
- A recent update on the connection between dietary phytochemicals and skin cancer: emerging understanding of the molecular mechanism.Annals of medicine and surgery (2012) · 2024Review
- Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second-line docetaxel: A randomized trial.Health science reports · 2024Article
- Phytochemicals Showing Antiangiogenic Effect in Pre-clinical Models and their Potential as an Alternative to Existing Therapeutics.Current topics in medicinal chemistry · 2024Review
- Pharmacotherapy and Nutritional Supplements for Neovascular Eye Diseases.Medicina (Kaunas, Lithuania) · 2023Review
- Is Curcumine Useful in the Treatment and Prevention of the Tendinopathy and Myotendinous Junction Injury? A Scoping Review.Nutrients · 2023Article
- Protective effects of Theracurmin treatment during experimental infection of the Colombian strain ofFrontiers in cellular and infection microbiology · 2023Article
- Article
- Nanoparticle-Based Therapeutics to Overcome Obstacles in the Tumor Microenvironment of Hepatocellular Carcinoma.Nanomaterials (Basel, Switzerland) · 2022Review
- Effect of Vitamin C on Tendinopathy Recovery: A Scoping Review.Nutrients · 2022Article
- Biological aspects in controlling angiogenesis: current progress.Cellular and molecular life sciences : CMLS · 2022Review
- Curcumin and Wnt/β‑catenin signaling in exudative age‑related macular degeneration (Review).International journal of molecular medicine · 2022Review
- Therapeutic potential of curcumin in diabetic retinopathy (Review).International journal of molecular medicine · 2021Review
- Curcumin Ameliorates Copper-Induced Neurotoxicity Through Inhibiting Oxidative Stress and Mitochondrial Apoptosis in SH-SY5Y Cells.Neurochemical research · 2021Article
- Natural Health Products (NHP's) and Natural Compounds as Therapeutic Agents for the Treatment of Cancer; Mechanisms of Anti-Cancer Activity of Natural Compounds and Overall Trends.International journal of molecular sciences · 2020Review
- Nanotechnology for angiogenesis: opportunities and challenges.Chemical Society reviews · 2020Review
- Formulation of More Efficacious Curcumin Delivery Systems Using Colloid Science: Enhanced Solubility, Stability, and Bioavailability.Molecules (Basel, Switzerland) · 2020Review
- Investigating the antiangiogenic potential ofSaudi journal of biological sciences · 2020Article
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundCurcumin is a small-molecular-weight compound that is isolated from the commonly used spice turmeric. In animal models, curcumin and its derivatives have been shown to inhibit the progression of chemically induced colon and skin cancers. The genetic changes in carcinogenesis in these organs involve different genes, but curcumin is effective in preventing carcinogenesis in both organs. A possible explanation for this finding is that curcumin may inhibit angiogenesis. MATERIALS AND
methodsCurcumin was tested for its ability to inhibit the proliferation of primary endothelial cells in the presence and absence of basic fibroblast growth factor (bFGF), as well as its ability to inhibit proliferation of an immortalized endothelial cell line. Curcumin and its derivatives were subsequently tested for their ability to inhibit bFGF-induced corneal neovascularization in the mouse cornea. Finally, curcumin was tested for its ability to inhibit phorbol ester-stimulated vascular endothelial growth factor (VEGF) mRNA production.
resultsCurcumin effectively inhibited endothelial cell proliferation in a dose-dependent manner. Curcumin and its derivatives demonstrated significant inhibition of bFGF-mediated corneal neovascularization in the mouse. Curcumin had no effect on phorbol ester-stimulated VEGF production.
conclusionsThese results indicate that curcumin has direct antiangiogenic activity in vitro and in vivo. The activity of curcumin in inhibiting carcinogenesis in diverse organs such as the skin and colon may be mediated in part through angiogenesis inhibition.
Indexed as
Identifiers
10780880PMC2230271W175416543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.